Does the media favor JANX or KROS?

In the previous week, Keros Therapeutics had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Keros Therapeutics and 5 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.62 beat Keros Therapeutics' score of 0.39 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KROS or REPL?

In the previous week, Keros Therapeutics had 5 more articles in the media than Replimune Group. MarketBeat recorded 8 mentions for Keros Therapeutics and 3 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.44 beat Keros Therapeutics' score of 0.39 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KROS or ORIC?

In the previous week, Keros Therapeutics had 4 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 8 mentions for Keros Therapeutics and 4 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.47 beat Keros Therapeutics' score of 0.39 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Keros Therapeutics (KROS) Competitors

$9.93 -0.14 (-1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$9.93 0.00 (-0.05%)

As of 04:42 PM Eastern

Compare

KROS vs. JANX, REPL, TBPH, ORIC, and ESPR

Should you buy Keros Therapeutics stock or one of its competitors? MarketBeat compares Keros Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Keros Therapeutics include Janux Therapeutics (JANX), Replimune Group (REPL), Theravance Biopharma (TBPH), Oric Pharmaceuticals (ORIC), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.

How does Keros Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Janux Therapeutics has a beta of 2.53, indicating that its stock price is 153% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Janux Therapeutics currently has a consensus price target of $45.85, suggesting a potential upside of 248.64%. Keros Therapeutics has a consensus price target of $20.40, suggesting a potential upside of 105.44%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Janux Therapeutics is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Keros Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	80.19	-$113.62M	-$1.84	N/A
Keros Therapeutics	$244.06M	0.81	$87.01M	-$3.01	N/A

Janux Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Janux Therapeutics' return on equity of -12.93% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Keros Therapeutics had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Keros Therapeutics and 5 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.62 beat Keros Therapeutics' score of 0.39 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Janux Therapeutics beats Keros Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Keros Therapeutics compare to Replimune Group?

Keros Therapeutics (NASDAQ:KROS) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Keros Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

In the previous week, Keros Therapeutics had 5 more articles in the media than Replimune Group. MarketBeat recorded 8 mentions for Keros Therapeutics and 3 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.44 beat Keros Therapeutics' score of 0.39 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Replimune Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Replimune Group has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Replimune Group	N/A	-102.69%	-72.22%

Keros Therapeutics has higher revenue and earnings than Replimune Group. Keros Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.81	$87.01M	-$3.01	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

Keros Therapeutics presently has a consensus target price of $20.40, indicating a potential upside of 105.44%. Replimune Group has a consensus target price of $4.88, indicating a potential downside of 42.44%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Keros Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 20.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Keros Therapeutics beats Replimune Group on 11 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Keros Therapeutics had 6 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Keros Therapeutics and 2 mentions for Theravance Biopharma. Keros Therapeutics' average media sentiment score of 0.39 beat Theravance Biopharma's score of -0.06 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Theravance Biopharma	Neutral
Keros Therapeutics	Neutral

Theravance Biopharma has a net margin of 104.34% compared to Keros Therapeutics' net margin of -256.60%. Theravance Biopharma's return on equity of 18.84% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Theravance Biopharma has higher earnings, but lower revenue than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	7.85	$105.89M	$2.20	7.44
Keros Therapeutics	$244.06M	0.81	$87.01M	-$3.01	N/A

Theravance Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Theravance Biopharma currently has a consensus price target of $21.83, indicating a potential upside of 33.37%. Keros Therapeutics has a consensus price target of $20.40, indicating a potential upside of 105.44%. Given Keros Therapeutics' higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Theravance Biopharma beats Keros Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Keros Therapeutics compare to Oric Pharmaceuticals?

Keros Therapeutics (NASDAQ:KROS) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 20.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Keros Therapeutics had 4 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 8 mentions for Keros Therapeutics and 4 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.47 beat Keros Therapeutics' score of 0.39 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Keros Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Keros Therapeutics currently has a consensus price target of $20.40, suggesting a potential upside of 105.44%. Oric Pharmaceuticals has a consensus price target of $19.36, suggesting a potential upside of 156.81%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Oric Pharmaceuticals has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Keros Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.81	$87.01M	-$3.01	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Summary

Oric Pharmaceuticals beats Keros Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to Esperion Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Keros Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

In the previous week, Keros Therapeutics had 7 more articles in the media than Esperion Therapeutics. MarketBeat recorded 8 mentions for Keros Therapeutics and 1 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.89 beat Keros Therapeutics' score of 0.39 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Keros Therapeutics	Neutral
Esperion Therapeutics	Very Positive

Keros Therapeutics currently has a consensus price target of $20.40, indicating a potential upside of 105.44%. Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 76.43%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Keros Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 20.6% of Keros Therapeutics shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Esperion Therapeutics has a net margin of 0.12% compared to Keros Therapeutics' net margin of -256.60%. Esperion Therapeutics' return on equity of -0.14% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Keros Therapeutics has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.81	$87.01M	-$3.01	N/A
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A

Summary

Keros Therapeutics and Esperion Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$199.30M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-3.30	10.45	20.85	21.87
Price / Sales	0.81	290.84	500.87	105.21
Price / Cash	2.22	120.20	43.05	54.72
Price / Book	0.64	8.00	10.43	6.70
Net Income	$87.01M	$23.89M	$3.56B	$337.26M
7 Day Performance	-5.43%	-3.49%	-1.39%	-1.41%
1 Month Performance	-17.73%	1.03%	0.86%	1.15%
1 Year Performance	-27.78%	34.39%	19.42%	22.61%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	3.2079 of 5 stars	$9.93 -1.4%	$20.40 +105.4%	-28.5%	$199.30M	$244.06M	N/A	100
JANX Janux Therapeutics	3.1873 of 5 stars	$13.76 +1.3%	$45.85 +233.2%	-47.5%	$828.78M	$10M	N/A	30	Positive News
REPL Replimune Group	1.3009 of 5 stars	$9.87 -1.1%	$4.88 -50.6%	-9.2%	$824.08M	N/A	N/A	210	Upcoming Earnings Gap Down
TBPH Theravance Biopharma	2.6574 of 5 stars	$16.37 +2.8%	$21.83 +33.4%	+50.6%	$820.72M	$109.78M	7.44	110	Analyst Downgrade
ORIC Oric Pharmaceuticals	2.5726 of 5 stars	$8.02 +2.3%	$19.36 +141.4%	-18.9%	$811.58M	N/A	N/A	80	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. JANX, REPL, TBPH, ORIC, and ESPR

How does Keros Therapeutics compare to Janux Therapeutics?

Summary

How does Keros Therapeutics compare to Replimune Group?

Summary

How does Keros Therapeutics compare to Theravance Biopharma?

Summary

How does Keros Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Esperion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. JANX, REPL, TBPH, ORIC, and ESPR

How does Keros Therapeutics compare to Janux Therapeutics?

Which has more risk & volatility, JANX or KROS?

Do analysts rate JANX or KROS?

Which has higher valuation & earnings, JANX or KROS?

Is JANX or KROS more profitable?

Do insiders and institutionals hold more shares of JANX or KROS?

Does the media favor JANX or KROS?

Summary

How does Keros Therapeutics compare to Replimune Group?

Which has more risk and volatility, KROS or REPL?

Does the media refer more to KROS or REPL?

Is KROS or REPL more profitable?

Which has preferable earnings & valuation, KROS or REPL?

Do analysts recommend KROS or REPL?

Do institutionals and insiders believe in KROS or REPL?

Summary

How does Keros Therapeutics compare to Theravance Biopharma?

Does the media favor TBPH or KROS?

Is TBPH or KROS more profitable?

Do institutionals & insiders have more ownership in TBPH or KROS?

Which has better valuation and earnings, TBPH or KROS?

Which has more volatility & risk, TBPH or KROS?

Do analysts rate TBPH or KROS?

Summary

How does Keros Therapeutics compare to Oric Pharmaceuticals?

Do institutionals & insiders hold more shares of KROS or ORIC?

Does the media favor KROS or ORIC?

Which has more volatility & risk, KROS or ORIC?

Do analysts recommend KROS or ORIC?

Is KROS or ORIC more profitable?

Which has preferable earnings & valuation, KROS or ORIC?

Summary

How does Keros Therapeutics compare to Esperion Therapeutics?

Which has more volatility and risk, KROS or ESPR?

Does the media refer more to KROS or ESPR?

Do analysts rate KROS or ESPR?

Do institutionals & insiders have more ownership in KROS or ESPR?

Is KROS or ESPR more profitable?

Which has better earnings and valuation, KROS or ESPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools